Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
← catalyst calendarNCT06122779 · readout in 117 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
227actual
Sites
86
Countries
Argentina, Canada, China +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-07 | actual | When the study began enrolling |
| Primary completion | 2026-12-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-14 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Heart Failure
Interventions
- Drug: BMS-986435 — also filed as MYK-224
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment emergent adverse events (TEAEs)
measured Up to approximately 24 weeks
Incidence of serious adverse events (SAEs)
measured Up to approximately 24 weeks
Incidence of AEs leading to treatment discontinuation
measured Up to approximately 20 weeks
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed